Elexacaftor/tezacaftor/ivacaftor (E/T/I) is approved for use in pwCF with at least one copy of the F508del‐CFTR variant or another responsive CFTR gene variant, making ~90% of US CF patients eligible for this highly effective modulator treatment (HEMT) [16, 20]. Here, CFTR is linked to cystic fibrosis.